Home / Health / UC Treatment Breakthrough: Disease Clearance Halves Complications
UC Treatment Breakthrough: Disease Clearance Halves Complications
19 Oct
Summary
- Disease clearance significantly reduces ulcerative colitis complications by nearly 70%.
- ENTYVIO trial provides first prospective evidence for disease clearance as a treatment target.
- Deeper remission achieved without corticosteroids improves long-term disease control.
A significant breakthrough in ulcerative colitis (UC) treatment has emerged from the VERDICT clinical trial, which investigated the impact of achieving corticosteroid-free (CSF) disease clearance versus symptomatic remission alone with ENTYVIO® (vedolizumab).
The trial revealed that patients treated to achieve disease clearance experienced a significantly longer time to their first UC-related complication, reducing complication risk by nearly 70%.
This Phase 4 study offers the first prospective, randomized evidence supporting disease clearance as a crucial treatment target for moderate to severe UC. It suggests that a treat-to-target strategy with ENTYVIO can alter the disease course.
VERDICT randomized adults to three treatment targets: symptomatic remission, symptomatic plus endoscopic remission, and disease clearance (symptomatic, endoscopic, and histologic remission). The primary endpoint was met, showing a longer time to complications for the disease clearance group.
Safety data from the trial over 96 weeks remained consistent with previous ENTYVIO findings, with no new safety signals identified. Molecular analyses also suggested restoration of gut function in bio-naïve patients achieving early disease clearance.
